BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point InhibitorsElizabeth Dudnik, Jair Bar, Damien Urban et al.|Journal of Thoracic Oncology|2018Cited by 220
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)Jair Bar, Alfredo Addeo, Nir Peled et al.|Journal of Thoracic Oncology|2022Cited by 97
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)Elizabeth Dudnik, Nir Peled, Elias Bshara et al.|Lung Cancer|2018Cited by 75
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world dataElizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg et al.|OncoImmunology|2021Cited by 70
Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitorsOded Icht, Avi Leader, Naama Darzi et al.|Journal of Thrombosis and Haemostasis|2021Cited by 61